Seagen touts full PhII Tukysa data as it plots colorectal cancer expansion

As rumors of a Merck buyout continue to swirl around Seagen, the big Seattle biotech is charging ahead with new data for its cancer drug Tukysa. Seagen reported full results Saturday from a Phase II study measuring Tukysa’s effectiveness in second-line HER2-positive metastatic colorectal cancer, after revealing a 38.1% overall…

Click here to view original post